Counterpoint Mutual Funds LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Counterpoint Mutual Funds LLC purchased a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,139 shares of the medical instruments supplier's stock, valued at approximately $297,000.

Other large investors have also modified their holdings of the company. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the fourth quarter valued at about $36,000. SRS Capital Advisors Inc. grew its stake in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial acquired a new stake in shares of Insulet in the fourth quarter valued at about $57,000. TD Private Client Wealth LLC boosted its holdings in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after purchasing an additional 56 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares during the last quarter.

Insider Activity at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.47% of the stock is owned by insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a report on Thursday, December 12th. Royal Bank of Canada assumed coverage on Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target for the company. Citigroup increased their price target on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Piper Sandler increased their price target on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, Raymond James reissued an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $292.06.

Insulet Stock Performance

Shares of Insulet stock traded up $2.93 on Friday, reaching $268.32. 1,299,442 shares of the company were exchanged, compared to its average volume of 690,091. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company's 50-day moving average is $272.04 and its two-hundred day moving average is $256.71. The firm has a market cap of $18.84 billion, a price-to-earnings ratio of 46.34, a P/E/G ratio of 3.62 and a beta of 1.29. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. As a group, research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.